Malignant B Cell Lymphoma clinical trials

Explore recruiting malignant b cell lymphoma clinical trials.

Recruiting malignant b cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Malignant B Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed or Aggressive Lymphoma (GOAL II)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Malignant B Cell Lymphoma trials by city

Malignant B Cell Lymphoma clinical trials

Recruiting malignant b cell lymphoma studies right now

CAR-T Followed by Bispecific Antibodies

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

CD70-targeted immunoPET Imaging of Malignant Cancers

AZA Combined With RCHOP in P53-mutated DLBCL.

Evaluation of Skin Tests in Biotherapy Allergies

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

A Study of NX-1607 in Adults With Advanced Malignancies

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Also recruiting in Europe

A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed or Aggressive Lymphoma (GOAL II)

Malignant B Cell Lymphoma trials by city

Other conditions